A detailed history of Entry Point Capital, LLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Entry Point Capital, LLC holds 13,651 shares of CNTA stock, worth $234,251. This represents 0.13% of its overall portfolio holdings.

Number of Shares
13,651
Previous 8,136 67.79%
Holding current value
$234,251
Previous $73.5 Million 99.7%
% of portfolio
0.13%
Previous 0.11%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.58 - $16.99 $47,318 - $93,699
5,515 Added 67.79%
13,651 $218,000
Q2 2024

Aug 13, 2024

SELL
$8.04 - $11.87 $12,059 - $17,805
-1,500 Reduced 15.57%
8,136 $73.5 Million
Q1 2024

May 14, 2024

BUY
$6.73 - $12.2 $64,850 - $117,559
9,636 New
9,636 $109 Million

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.62B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.